Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Euroapi S.A.S.U. is a leading pharmaceutical company specializing in the development, manufacturing, marketing, and distribution of active pharmaceutical ingredients (APIs) and intermediates for human and veterinary medicines. With approximately 200 products in its portfolio, it offers one of the largest selections in the industry, leveraging advanced technologies such as solid phase chemistry, particle engineering, microbial fermentation, small molecule synthesis, prostaglandins, steroids, hormones, opiates, controlled substances, and lipids. Euroapi serves a broad range of clients including pharmaceutical firms, generic drug manufacturers, biotechnology companies, animal health product makers, consumer health, nutrition, cosmetic product companies, and contract development manufacturing organizations. Positioned as a critical player in the healthcare sector, particularly in drug manufacturers—specialty and generic—it supports global pharmaceutical innovation, regulatory compliance, and supply chain efficiency from its base in Paris, France, where it was incorporated in 2020 and employs around 3,187 people.
Operating margin is thin at 0.20%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue declined 7.2% YoY. The question is whether this is cyclical or a structural shift.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
€853M
▼ -7.2% YoY
Net Income (TTM)
-€211M
▼ -61.7% YoY
Op. Margin
0.20%
▲ +1.3pp YoY
ROIC
0.14%
▲ +0.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
€50M
▲ +235.6% YoY
Op. Cash Flow (TTM)
€127M
▲ +24.8% YoY
Net Debt
-€54M
Net Cash Position
Cash & Equiv.
€120M
3Y CAGR: -4.6%
Continue Research